SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy ?
Source: Globenewswire
FDA Developments: The FDA lifted the clinical hold on ibrexafungerp, allowing SCYNEXIS to resume the Phase 3 MARIO study for invasive candidiasis, despite a disagreement with GSK regarding the study's continuation. Hansoh has also received approval in China for ibrexafungerp, which will provide SCYNEXIS with milestone payments and royalties.
Financial Overview: SCYNEXIS reported a net loss of $5.4 million for Q1 2025, with cash reserves of $53.8 million expected to last until Q3 2026. The company is advancing its second-generation fungicide candidate, SCY-247, with initial Phase 1 data anticipated in Q3 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
